These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28611636)

  • 21. [Treatment-related Skin Toxicity Caused by Programmed Death-1 Inhibitor Nivolumab: 
A Case Report].
    Gao L; Yu Y; Lu S
    Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):250-254. PubMed ID: 31014445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report.
    Hatakeyama Y; Ohnishi H; Suda K; Okamura K; Shimada T; Yoshimura S
    J Oncol Pharm Pract; 2019 Dec; 25(8):2023-2026. PubMed ID: 30526346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review.
    Dudzińska M; Szczyrek M; Wojas-Krawczyk K; Świrska J; Chmielewska I; Zwolak A
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6].
    Okiyama N; Tanaka R
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):95-101. PubMed ID: 28603207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
    Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
    J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis.
    Schneider S; Potthast S; Komminoth P; Schwegler G; Böhm S
    Case Rep Oncol; 2017; 10(2):473-478. PubMed ID: 28626408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
    Imai Y; Tanaka M; Fujii R; Uchitani K; Okazaki K
    Yakugaku Zasshi; 2019; 139(3):491-495. PubMed ID: 30828027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.
    Cooper DS; Meriggioli MN; Bonomi PD; Malik R
    J Neuromuscul Dis; 2017; 4(2):169-173. PubMed ID: 28505981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
    Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
    Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
    Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.
    Chen R; Tao Y; Xu X; Shan L; Jiang H; Yin Q; Pei L; Cai F; Ma L; Yu Y
    Discov Med; 2018 Oct; 26(143):155-166. PubMed ID: 30586539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient.
    Araújo M; Ligeiro D; Costa L; Marques F; Trindade H; Correia JM; Fonseca C
    Immunotherapy; 2017 Jun; 9(7):531-535. PubMed ID: 28595520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
    Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
    Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect and biomarker of Nivolumab for non-small-cell lung cancer.
    Wang L; Zhao D; Qin K; Rehman FU; Zhang X
    Biomed Pharmacother; 2019 Sep; 117():109199. PubMed ID: 31387181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
    Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
    Front Immunol; 2018; 9():1769. PubMed ID: 30108590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
    Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
    BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of autoimmune thyroiditis in patients with type 1 diabetes: a long-term follow-up study.
    Hwang GB; Yoon JS; Park KJ; Lee HS; Hwang JS
    Ann Pediatr Endocrinol Metab; 2018 Mar; 23(1):33-37. PubMed ID: 29609447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.